Literature DB >> 28869932

Pirfenidone in Idiopathic Pulmonary Fibrosis "RECAP-itulating Safety into the Real World".

Argyris Tzouvelekis1, Evangelos Bouros, Vasilios Tzilas, Demosthenes Bouros.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28869932     DOI: 10.1159/000480299

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


× No keyword cloud information.
  3 in total

1.  Role of dual-specificity protein phosphatase DUSP10/MKP-5 in pulmonary fibrosis.

Authors:  Nikos Xylourgidis; Kisuk Min; Farida Ahangari; Guoying Yu; Jose D Herazo-Maya; Theodoros Karampitsakos; Vassilis Aidinis; Leonhard Binzenhöfer; Demosthenes Bouros; Anton M Bennett; Naftali Kaminski; Argyrios Tzouvelekis
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-04       Impact factor: 5.464

2.  Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Authors:  Argyrios Tzouvelekis; Theodoros Karampitsakos; Paschalis Ntolios; Vasilios Tzilas; Evangelos Bouros; Evangelos Markozannes; Ioanna Malliou; Aris Anagnostopoulos; Andreas Granitsas; Paschalis Steiropoulos; Katerina Dimakou; Serafeim Chrysikos; Nikolaos Koulouris; Demosthenes Bouros
Journal:  Front Med (Lausanne)       Date:  2017-11-29

Review 3.  The Management of Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Paolo Spagnolo; Argyris Tzouvelekis; Francesco Bonella
Journal:  Front Med (Lausanne)       Date:  2018-07-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.